Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.
2.
3.
4.

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL, Catalona WJ.

J Urol. 2006 Mar;175(3 Pt 1):902-6.

PMID:
16469576
5.
6.

Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancer.

Zhu H, Roehl KA, Antenor JA, Catalona WJ.

J Urol. 2004 Feb;171(2 Pt 1):661-3.

PMID:
14713781
7.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x.

8.

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.

Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ.

J Urol. 1996 Mar;155(3):816-20. Review.

PMID:
8583583
10.

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH.

Prostate. 2001 Jun 1;47(4):252-61.

PMID:
11398172
11.
12.
13.

Prostate biopsy: who, how and when. An update.

Djavan B, Milani S, Remzi M.

Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Review.

PMID:
15780165
14.

Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).

Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.

J Med Assoc Thai. 2006 Jan;89(1):37-42.

PMID:
16583579
15.

Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.

Djavan B, Fong YK, Ravery V, Remzi M, Horninger W, Susani M, Kreuzer S, Boccon-Gibod L, Bartsch G, Marberger M.

Eur Urol. 2005 Jan;47(1):38-44; discussion 44.

PMID:
15582247
16.
17.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

18.

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.

Urology. 2006 Aug;68(2):342-7.

PMID:
16904449
19.

The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.

Gosselaar C, Roobol MJ, Roemeling S, Schröder FH.

Eur Urol. 2008 Sep;54(3):581-8. doi: 10.1016/j.eururo.2008.03.104.

PMID:
18423977
20.

Prevalence of undiagnosed prostate cancer in men with erectile dysfunction.

Sairam K, Kulinskaya E, Boustead GB, Hanbury DC, McNicholas TA.

BJU Int. 2002 Feb;89(3):261-3.

Items per page

Supplemental Content

Support Center